Terminated PHASE3 INTERVENTIONAL 1-arm NCT00988052

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

A Multinational, Multicenter, Open-label, Single-assignment Extension of the MS-LAQ-301 (ALLEGRO) Study, to Evaluate the Long-term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects With Relapsing MS

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Conditions Relapsing Multiple Sclerosis

Interventions Laquinimod

Updated 15 times since 2017 Last updated: Dec 7, 2021 Started: Nov 10, 2009 Primary completion: Jul 1, 2017 Completion: Jul 1, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor terminated RRMS studies as sufficient long term clinical data was collected for the study drug in the relevant dose.

Listed as NCT00988052, this PHASE3 trial focuses on Relapsing Multiple Sclerosis and remains terminated or withdrawn. Sponsored by Teva Branded Pharmaceutical Products R&D, Inc., it has been updated 15 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

15 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE3
Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2022 — Jul 2024 [monthly]

Terminated PHASE3

▶ Show 10 earlier versions

Dec 2021 — Jan 2022 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Nov 2020 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2019 — Nov 2020 [monthly]

Terminated PHASE3
Jul 2018 — Feb 2019 [monthly]

Terminated PHASE3
Jun 2018 — Jul 2018 [monthly]

Terminated PHASE3
May 2018 — Jun 2018 [monthly]

Terminated PHASE3
Oct 2017 — May 2018 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated
Feb 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Teva Branded Pharmaceutical Products R&D, Inc.

Data source: Teva Branded Pharmaceutical Products R&D, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barcelona, Spain , Bayreuth, Germany , Beade-Pontevedra, Spain , Bedford, Canada , Belgrade, Serbia , Berlin, Germany , Besançon, France , Bochum, Germany , Bron, France , Bucharest, Romania and 107 more locations